Loading...
Randomized phase II dose optimization study of inobrodib (CCS1477), in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM)
Joseph, N. Campbell, V. Pawlyn, C. Vogl, D. Holstein, S. Gooding, S. Creasey, T. Jenner, M. Chaidos, A. Rodriguez-Otero, P.
Joseph, N.
Campbell, V.
Pawlyn, C.
Vogl, D.
Holstein, S.
Gooding, S.
Creasey, T.
Jenner, M.
Chaidos, A.
Rodriguez-Otero, P.
Abstract
Description
Date
2025
Publisher
Collections
Files
Loading...
Found from Unpaywall
Adobe PDF, 172.22 KB
Keywords
Type
Article
Citation
Joseph N, Campbell V, Pawlyn C, Vogl D, Holstein S, Gooding S, et al. Randomized phase II dose optimization study of inobrodib (CCS1477), in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM). Blood. 2025 NOV 3;146:4035-6.